Navigation Links
Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results
Date:3/11/2009

2,939 2,135 11,699 7,581 Operating expenses: Cost of goods sold - - - 576 Research and development 5,353 4,614 21,047 19,198 Selling, general and administrative 1,324 865 5,063 8,246 Total expenses 6,677 5,479 26,110 28,020 Operating loss (3,738) (3,344) (14,411) (20,439) Interest income 47 264 500 1,159 Interest expense (273) (217) (1,256) (682) Loss on investments - - (500) - Net loss $(3,964) $(3,297) $(15,667) $(19,962) Basic and diluted net loss per share $(0.03) $(0.03) $(0.13) $(0.17) Shares used in computing Basic and diluted net loss per share 122,318 121,812 122,132 114,682

                             INSMED INCORPORATED
                   Consolidated Statements of Cash Flows
                        (in thousands - unaudited)

                                                     Twelve Months Ended
                                                        December 31,
                                                     2008           2007
     Operating activities
     Net loss                                    $(15,667)      $(19,962)
     Adjustments to reconcile net loss
      to net cash used in operating
      activities:
        Depreciation and amortization               1,043            406
        Stock based compensation expense              850            521
        Stock options issued for services             147             38
        Realized loss on investments                  500              -
        Changes in operating ass
'/>"/>
SOURCE Insmed Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Insmed Appoints Dennis M. Lanfear to Board Of Directors
2. Insmed Awarded $2.1 Million by Muscular Dystrophy Association
3. Insmed to Appeal Delisting Notification From Nasdaq
4. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
5. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
6. Insmed to Host Fourth Quarter and Full-Year 2007 Conference Call
7. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
8. Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
9. Insmed Announces Additional Information in Compliance With NASDAQ Rules
10. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
11. Insmed to Present at CBI Follow-On Biologics Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Sept. 19, 2014  An entire month is dedicated ... neuropathies – Charcot-Marie-Tooth disease (CMT) – a debilitating neuromuscular ... extreme muscle atrophy, weakness, and foot and hand deformities. ... millions worldwide. CMT is a progressive disease, and over ... requiring mobility devices such as leg braces, wheelchairs and ...
(Date:9/19/2014)... 19, 2014  Nektar Therapeutics (NASDAQ: ... characterizing the analgesic profiles of a series of ... agonist molecules. The preclinical research candidates were created ... The analgesic properties of kappa receptor ... 1,2 Kappa opioid receptors are expressed in ...
(Date:9/19/2014)... SPRINGS, Florida , September 19, 2014 ... companies release latest developments, patents and results of studies ... GNSZ), Eli Lilly and Company (NYSE: LLY ... Celgene Corporation (NASDAQ: CELG ) and Arena ... GNSZ), a leader in developing prodrug therapeutics for the ...
(Date:9/19/2014)... September 19, 2014 Cereal grain ... industries will gather October 5–8, 2014, for the ... Island Convention Center in Providence, Rhode Island. The ... work of food scientists, chemists, microbiologists, nutritionists, and ... food production management. To date, 1,000 attendees have ...
Breaking Biology Technology:September is Charcot-Marie-Tooth (CMT) Awareness Month - Scheduled events, activities and important partnerships announced throughout the month! 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 2Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 3
... March 9, 2011 Palatin Technologies, Inc. (NYSE Amex: ... the ROTH 23rd Annual OC Growth Stock Conference on Tuesday, ... will be held at the Ritz Carlton Laguna Niguel in ... and Chief Executive Officer of Palatin Technologies, will provide an ...
... Corp. (Nasdaq: BSTC ), a biopharmaceutical company ... it will host a conference call and live audio ... to report its fourth quarter and full year 2010 ... in the conference call, please dial 800-860-2442 (domestic) or ...
... 2011 Pioneer Surgical Technology today announces the market ... to be used in extremities and pelvis. ... 2011 American College of Foot and Ankle Surgeons (ACFAS) ... newest Biologics product, Legato™, will be included. Legato is ...
Cached Biology Technology:Pioneer® Surgical Technology, Inc. Enters the Biologics Extremities and Pelvis Market 2
(Date:9/21/2014)... Biochemists working at the University of California, San Diego, ... chemical marks that control the activity of genes based ... report results from its application to human embryonic cells ... online September 21. , "All of our cells have ... separate functions," said John Whitaker, lead author of the ...
(Date:9/19/2014)... dinosaurs a newly discovered hadrosaur with a ... Rhinorex condrupus by paleontologists from North ... in what is now Utah approximately 75 million ... Rhinorex, which translates roughly into "King Nose," was ... Cretaceous hadrosaurs like Parasaurolophus and Edmontosaurus. Hadrosaurs are ...
(Date:9/19/2014)... years has adapted to the arctic cold, and then you ... for you. , This is happening to the small white ... called nonylphenol, comes from the use of certain detergents, pesticides ... disruptor, but when entering the worm it has another dangerous ... in its body from cold damage. , Enchytraeus albidus ...
Breaking Biology News(10 mins):Program predicts placement of chemical tags that control gene activity 2New hadrosaur noses into spotlight 2Environmental pollutants make worms susceptible to cold 2Environmental pollutants make worms susceptible to cold 3
... obesity in the United States is reaching epidemic proportions. With ... time television devoted to foods and beverages and continuing questions ... the November/December issue of the Journal of Nutrition Education ... might be a large contributor to the problem. Researchers ...
... laboratory that deciphered the DNA codes, or genomes, of the ... Genome 10K Project, an international effort to build an invaluable ... conducting comparative studies on a scale that currently can not ... in a paper published in the Nov. 5, 2009 issue ...
... VALLEY, Calif., Oct. 19 Spectros, developer and manufacturer ... light on life-threatening diseases, announced today that it has ... Tissue Oximeter and Sensors. The markets covered include ... Suriname, Italy, France, Spain, Portugal, Poland, Greece, Turkey, and ...
Cached Biology News:TV bombards children with commercials for high-fat and high-sugar foods 2TV bombards children with commercials for high-fat and high-sugar foods 3Singapore scientists join international study of 10,000 vertebrates' genomes 2Spectros Signs New International Distribution Deals 2
... AS-2057 are fully automatic sample injection systems ... of precision. Sampling flexibility is unparalleled with ... automation and combinatorial chemistry. Also available is ... standard rack for 50 2,ml vials. The ...
... Rotofor purification system, 100-120 V, is used ... isoelectric focusing (IEF). The system includes both ... ml) focusing chambers, chassis, harvesting apparatus, cooling ... (pH 3-10), 60 ml syringe, colored protein ...
...
... SIGNETs BCIP/NBT Chromogen system consists ... chromogen in a single component,solution. ... in the presence of alkaline ... with minimal background noise. ,The ...
Biology Products: